You are here

Tremfya

J&J still sees plenty of opportunity in crowded immunology markets—starting with psoriasis

Fierce Pharma

Wed, 01/9/19 - 12:56 pm

Tremfya Demonstrates Superiority Over Cosentyx in Ph III Data in Moderate to Severe Plaque Psoriasis

CP Wire

Wed, 12/12/18 - 10:50 am

chronic plaque psoriasis

Tremfya Demonstrates Superiority Over Cosentyx in Ph III Data in Moderate to Severe Plaque Psoriasis

Wed, 12/12/18 - 10:46 am

chronic plaque psoriasis

Ph III Trial Shows Improved Outcomes with Tremfya after Failure With Humira

CP Wire

Wed, 09/12/18 - 11:08 am

Janssen Pharmaceuticals

chronic plaque psoriasis

clinical trials

Ph III Trial Shows Improved Outcomes with Tremfya after Failure With Humira

Wed, 09/12/18 - 09:16 am

Janssen Pharmaceuticals

chronic plaque psoriasis

Johnson & Johnson, looking for its Tremfya niche, starts up new trial program in Crohn's

Fierce Pharma

Wed, 07/11/18 - 11:35 am

Crohn's Disease

clinical trials

Johnson & Johnson’s Tremfya Approved for Reimbursement in the UK and Germany

CP Wire

Wed, 06/13/18 - 10:19 pm

Johnson & Johnson’s Tremfya Approved for Reimbursement in the UK and Germany

Wed, 06/13/18 - 10:19 pm

In a crowded market, AbbVie may still have a best-in-class psoriasis prospect up its sleeve: analyst

Fierce Pharma

Wed, 12/6/17 - 09:53 am

J&J's Tremfya approved, further crowding IL-inhibitor market

BioPharma Dive

Sat, 07/15/17 - 11:31 am

Interleukin-inhibitors

Pages